Literature DB >> 11583913

Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity.

C Liebmann1.   

Abstract

G protein-coupled receptors (GPCRs) can stimulate the mitogen-activated protein kinase (MAPK) cascade and thereby induce cellular proliferation like receptor tyrosine kinases (RTKs). Work over the past 5 years has established several models which reduce the links of G(i)-, G(q)-, and G(s)-coupled receptors to MAPK on few principle pathways. They include (i) Ras-dependent activation of MAPK via transactivation of RTKs such as the epidermal growth factor receptor (EGFR), (ii) Ras-independent MAPK activation via protein kinase C (PKC) that converges with the RTK signalling at the level of Raf, and (iii) activation as well as inactivation of MAPK via the cAMP/protein kinase A (PKA) pathway in dependency on the type of Raf. Most of these generalizing hypotheses are founded on experimental data obtained from expression studies and using a limited set of individual receptors. This review will compare these models with pathways to MAPK found for a great variety of peptide hormone and neuropeptide receptor subtypes in various cells. It becomes evident that under endogenous conditions, the transactivation pathway is less dominant as postulated, whereas pathways involving isoforms of PKC and, especially, phosphoinositide 3-kinase (PI-3K) appear to play a more important role as assumed so far. Highly cell-specific and unusual connections of signalling proteins towards MAPK, in particular tumour cells, might provide points of attacks for new therapeutic concepts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583913     DOI: 10.1016/s0898-6568(01)00192-9

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  62 in total

1.  Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Authors:  Delphine Mousseaux; Lionel Le Gallic; Joanne Ryan; Catherine Oiry; Didier Gagne; Jean-Alain Fehrentz; Jean-Claude Galleyrand; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

2.  Ligand-mediated dephosphorylation signaling for MAP kinase.

Authors:  Nataliia V Shults; Faisal S Almansour; Vladyslava Rybka; Dante I Suzuki; Yuichiro J Suzuki
Journal:  Cell Signal       Date:  2018-09-10       Impact factor: 4.315

3.  SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons.

Authors:  Ying Li; Wei Xu; Michael W McBurney; Valter D Longo
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

Review 4.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

5.  Transcription factor ets-2 plays an important role in the pathogenesis of pulmonary fibrosis.

Authors:  Christopher P Baran; Sara N Fischer; Gerard J Nuovo; Mohamed N Kabbout; Charles L Hitchcock; Benjamin D Bringardner; Sara McMaken; Christie A Newland; Carmen Z Cantemir-Stone; Gary S Phillips; Michael C Ostrowski; Clay B Marsh
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-11       Impact factor: 6.914

6.  A mitogen-activated protein kinase cascade regulating infection-related morphogenesis in Magnaporthe grisea.

Authors:  Xinhua Zhao; Yangseon Kim; Gyungsoon Park; Jin-Rong Xu
Journal:  Plant Cell       Date:  2005-03-04       Impact factor: 11.277

7.  Regulatory mechanisms of fear extinction and depression-like behavior.

Authors:  Natalie C Tronson; Christina Schrick; Andre Fischer; Farahnaz Sananbenesi; Gilles Pagès; Jacques Pouysségur; Jelena Radulovic
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

8.  Phosphorylation and intramolecular stabilization of the ligand binding domain in the nuclear receptor steroidogenic factor 1.

Authors:  Marion Desclozeaux; Irina N Krylova; Florence Horn; Robert J Fletterick; Holly A Ingraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice.

Authors:  Xi-Wei Ji; Shuang-Min Ji; Run-Tao Li; Ke-Hua Wu; Xiao Zhu; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

10.  Increased cell growth due to a new lipase-GEF (Phospholipase D2) fastly acting on Ras.

Authors:  Karen M Henkels; Madhu Mahankali; Julian Gomez-Cambronero
Journal:  Cell Signal       Date:  2012-08-31       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.